|
|
CAP及FAST评分在肝移植术后新发非酒精性脂肪肝中的应用价值探讨
|
Abstract:
目的：分析受控衰减参数(controlled attenuation parameter, CAP)以及FAST评分在评估肝移植(Liver transplantation, LT)后新发非酒精性脂肪肝(nonalcoholic fatty liver disease, NAFLD)中的应用价值。方法：这是一项单中心、前瞻性研究，对2014~2021年接受LT并在青岛大学附属医院器官移植中心规律随访的成年LT受者进行腹部超声检查及瞬态弹性成像(Transient elastography, TE)检测，建立受试者工作(receiver operating characteristic, ROC)曲线分析CAP在评估LT后新发NAFLD方面的应用价值，并通过计算FibroScan-天冬氨酸氨基转移酶评分(FibroScan-aspartate aminotransferase score, FAST)以评估LT后新发NAFLD患者的非酒精性脂肪性肝炎(nonalcoholic steatohepatitis, NASH)进展风险。结果：本研究对符合纳入标准的113例LT受者进行了TE检测，LT手术至TE检测的中位时间为3.3 (2.2~4.5)年，新发NAFLD的发病率为35.4% (40/113)，其中，52.5% (21/40)为轻度NAFLD，22.5% (9/40)为中度NAFLD，25.0% (10/40)为重度NAFLD。CAP诊断LT后新发NAFLD、LT后中–重度NAFLD及重度NAFLD的ROC曲线下面积分别为0.80 (0.70~0.90)、0.95 (0.89~1.00)和0.99 (0.97~1.00)，截止值分别为240.5 dB/m、264.5 dB/m和296.0 dB/m，且FAST值与LT后NASH进展高风险密切相关(P = 0.001)。单因素分析表明，LT后新发NAFLD患者的白蛋白水平(P = 0.039)、ALT水平(P = 0.029)、AST水平(P = 0.004)以及重度NAFLD (P = 0.044)与NASH高风险显著相关，而多因素分析提示，AST水平(OR 1.394, 95%CI 1.052~1.847, P = 0.021)是LT后新发NAFLD患者NASH进展高风险的独立危险因素。结论：CAP是LT后新发NAFLD患者诊断和严重程度分级的良好工具，具有良好的敏感性和特异性，尤其是在中度至重度LT后新发NAFLD中诊断性能尤为突出，可以用于量化LT后新发NAFLD。在LT后新发NAFLD患者中，FAST评分可用来评估其NASH进展风险，监测AST水平对预防LT后新发NAFLD患者NASH进展具有重要意义。
Aims: This study aimed to determine of the utility of controlled attenuation parameter (CAP) and FibroScan-AST (FAST) score in the evaluation of de-novo nonalcoholic fatty liver disease (de-novo NAFLD) after liver transplantation (LT). Methods: In this prospective, single-center study, ab-dominal ultrasound and Transient Elastography (TE) were performed for adult patients who un-derwent LT between 2014 and 2021, and were regularly followed up at the Organ Transplantation Center of the Affiliated Hospital of Qingdao University. Receiver operating characteristics (ROC) curve was constructed to determine the diagnostic performance of CAP in the detection of de-novo NAFLD after LT, and the FAST score was calculated to assess de-novo NAFLD patients at risk of pro-gressive NASH. Results: A total of 113 LT recipients were included in the study. The median period from LT to TE detection was 3.3 (2.2~4.5) years. The incidence of de-novo NAFLD was 35.4% (40/113), of which 52.5% (21/40) had mild NAFLD, 22.5% (9/40) had moderate NAFLD, and 25.0% (10/40) had severe NAFLD. CAP diagnosed de-novo NAFLD, moderate-severe NAFLD, and severe NAFLD with the area under the ROC curves (AUROC) mean 0.80 (0.70~0.90), 0.95 (0.89~1.00), and 0.99 (0.97~1.00), respectively. The cut-off values were 240.5 dB/m, 264.5 dB/m, and 296.0 dB/m, respectively. The FAST score identifying the risk of progressive NASH was significantly correlated with the
| [1] | Martin, P., DiMartini, A., Feng, S., Brown Jr., R. and Fallon, M. (2014) Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology, 59, 1144-1165. https://doi.org/10.1002/hep.26972 |
| [2] | Roberts, M.S., Angus, D.C., Bryce, C.L., Valenta, Z. and Weissfeld, L. (2004) Survival after Liver Transplantation in the United States: A Dis-ease-Specific Analysis of the UNOS Database. Liver Transplantation, 10, 886-897.
https://doi.org/10.1002/lt.20137 |
| [3] | Spiritos, Z. and Abdelmalek, M.F. (2021) Metabolic Syndrome Following Liver Transplantation in Nonalcoholic Steatohepatitis. Translational Gastroenterology and Hepatology, 6, 13. https://doi.org/10.21037/tgh.2020.02.07 |
| [4] | Gitto, S., et al. (2018) De-Novo Nonalcoholic Steatohepatitis Is As-sociated with Long-Term Increased Mortality in liver Transplant Recipients. European Journal of Gastroenterology & Hepatology, 30, 766-773.
https://doi.org/10.1097/MEG.0000000000001105 |
| [5] | Galvin, Z., et al. (2019) Predictors of De Novo Nonalco-holic Fatty Liver Disease after Liver Transplantation and Associated Fibrosis. Liver Transplantation, 25, 56-67. https://doi.org/10.1002/lt.25338 |
| [6] | Karlas, T., et al. (2015) Noninvasive Characterization of Graft Steatosis after Liver Transplantation. Scandinavian Journal of Gastroenterology, 50, 224-232. https://doi.org/10.3109/00365521.2014.983156 |
| [7] | Esterson, Y.B. and Grimaldi, G.M. (2018) Radiologic Imag-ing in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinical Liver Disease, 22, 93-108. https://doi.org/10.1016/j.cld.2017.08.005 |
| [8] | Chayanupatkul, M., Dasani, D.B., Sogaard, K. and Schiano, T.D. (2021) The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elas-tography with Controlled Attenuation Parameter. Transplantation Proceedings, 53, 159-165. https://doi.org/10.1016/j.transproceed.2020.02.160 |
| [9] | Mikolasevic, I., et al. (2021) Noninvasive Markers of Liv-er Steatosis and Fibrosis after Liver Transplantation—Where Do We Stand? World Journal of Transplantation, 11, 37-53. https://doi.org/10.5500/wjt.v11.i3.37 |
| [10] | Eddowes, P.J., et al. (2019) Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalco-holic Fatty Liver Disease. Gastroenterology, 156, 1717-1730. https://doi.org/10.1053/j.gastro.2019.01.042 |
| [11] | Siddiqui, M.S., et al. (2021) Diagnostic Performance of Vibra-tion-Controlled Transient Elastography in Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 19, 367-374. https://doi.org/10.1016/j.cgh.2020.03.067 |
| [12] | Newsome, P.N., et al. (2020) FibroScan-AST (FAST) Score for the Non-Invasive Identification of Patients with Non-Alcoholic Steatohepatitis with Significant Activity and Fi-brosis: A Prospective Derivation and Global Validation Study. The Lancet Gastroenterology and Hepatology, 5, 362-373. https://doi.org/10.1016/S2468-1253(19)30383-8 |
| [13] | Fujii, H., et al. (2021) The FibroScan-Aspartate Aminotransferase Score Can Stratify the Disease Severity in a Japanese Cohort with Fatty Liver Diseases. Scientific Re-ports, 11, 13844. https://doi.org/10.1038/s41598-021-93435-x |
| [14] | Chinese Society of Hepatology Chinese Medi-cal Association; Chinese Society of Gastroenterology Chinese Medical Association; Chinese Society of Infectious Dis-eases, Chinese Medical Association (2019) Consensus on the Diagnosis and Therapy of Hepatic Fibrosis in. Chinese Journal of Hepatology, 27, 657-667. |
| [15] | Tokushige, K., et al. (2021) Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonal- coholic Steatohepatitis 2020. Journal of Gastroenterology, 56, 951-963. https://doi.org/10.1007/s00535-021-01796-x |
| [16] | Tejedor-Tejada, J., et al. (2021) De-Novo Nonalcoholic Fatty Liver Disease at 5 Years after Liver Transplantation: Prevalence and Predictive Factors. European Journal of Gastroen-terology & Hepatology, 33, 399-406.
https://doi.org/10.1097/MEG.0000000000001736 |
| [17] | Vallin, M., et al. (2014) Recurrent or de Novo Nonalcoholic Fatty Liver Disease after Liver Transplantation: Natural History Based on Liver Biopsy Analysis. Liver Transplantation, 20, 1064-1071. https://doi.org/10.1002/lt.23936 |
| [18] | Jones, N.R., et al. (2020) Diagnosis and Management of Hy-pertension in Adults: NICE Guideline Update 2019. British Journal of General Practice, 70, 90-91. https://doi.org/10.3399/bjgp20X708053 |
| [19] | Jia, W., et al. (2019) Standards of Medical Care for Type 2 Diabetes in China 2019. Diabetes/Metabolism Research and Reviews, 35, e3158. https://doi.org/10.1002/dmrr.3158 |
| [20] | Fan, J.G., Wei, L. and Zhuang, H. (2019) Guidelines of Prevention and Treatment of Nonalcoholic Fatty Liver Disease (2018, China). Journal of Digestive Diseases, 20, 163-173. https://doi.org/10.1111/1751-2980.12685 |
| [21] | Dumortier, J., et al. (2010) Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients: Another Story of “Seed and Soil”. The American Journal of Gastroenterology, 105, 613-620. https://doi.org/10.1038/ajg.2009.717 |
| [22] | Sasso, M., et al. (2010) Controlled Attenuation Parameter (CAP): A Novel VCTE？ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes. Ultrasound in Medicine and Biology, 36, 1825-1835.
https://doi.org/10.1016/j.ultrasmedbio.2010.07.005 |
| [23] | Darweesh, S.K., et al. (2019) The Clinical Usefulness of Elastography in the Evaluation of Nonalcoholic Fatty Liver Disease Patients: A Biopsy-Controlled Study. European Journal of Gastroenterology & Hepatology, 31, 1010-1016.
https://doi.org/10.1097/MEG.0000000000001365 |
| [24] | de Lédinghen, V., et al. (2014) Controlled Attenuation Pa-rameter (CAP) for the Diagnosis of Steatosis: A Prospective Study of 5323 Examinations. Journal of Hepatology, 60, 1026-1031. https://doi.org/10.1016/j.jhep.2013.12.018 |
| [25] | Cardoso, A.C., et al. (2022) Validation and Perfor-mance of FibroScan？-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 67, 5272-5279.
https://doi.org/10.1007/s10620-021-07363-x |
